Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer

Annals of Surgical Oncology

Volumn 10, Issue 8, 2003, Pages 882-889

  House, Michael G ^a,b   Wistuba, Ignacio I ^c   Argani, Pedram ^a   Guo, MingZhou ^b   Schulick, Richard D ^a   Hruban, Ralph H ^b   Herman, James G ^b   Maitra, Anirban ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Cancer; Gallbladder; Methylation; Tumor suppressor genes

Indexed keywords

APC PROTEIN; METHYLGUANINE METHYLTRANSFERASE; METHYLTRANSFERASE; PROTEIN MLH1; PROTEIN P16; PROTEIN P73; RETINOIC ACID RECEPTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GENETICS; CARCINOGENESIS; CHILE; CHOLELITHIASIS; CHRONIC CHOLECYSTITIS; CONTROLLED STUDY; FEMALE; GALLBLADDER CANCER; GALLBLADDER CARCINOMA; GENE FUNCTION; GENE LOCATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION; POLYMERASE CHAIN REACTION; PROMOTER REGION; TUMOR SUPPRESSOR GENE; UNITED STATES; ADENOCARCINOMA; ADOLESCENT; CHILD; CHOLECYSTITIS; CHRONIC DISEASE; DNA METHYLATION; GALLBLADDER TUMOR; GENETICS; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CHILE; CHOLECYSTITIS; CHRONIC DISEASE; DNA METHYLATION; FEMALE; GALLBLADDER NEOPLASMS; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); UNITED STATES;

EID: 1042274553     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2003.02.014     Document Type: Article

References (47)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001;51:349-64.
3. Nervi F, Duarte I, Gomez G, et al. Frequency of gallbladder cancer in Chile, a high-risk area. Int J Cancer 1988;41:657-60.
4. Khan ZR, Neugut AI, Ahsan H, Chabot JA. Risk factors for biliary tract cancers. Am J Gastroenterol 1999;94:149-52.
5. Kimura K, Ohto M, Saisho H, et al. Association of gallbladder carcinoma and anomalous pancreaticobiliary ductal union. Gastroenterology 1985;89:1258-65.
6. Strom BL, Soloway RD, Rios-Dalenz JL, et al. Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer 1995;76:1747-56.
7. Caygill CP, Hill MJ, Braddick M, Sharp JC. Cancer mortality in chronic typhoid and paratyphoid carriers. Lancet 1994;343:83-4.
8. Ajiki T, Fujimori T, Onoyama H, et al. K-ras gene mutation in gall bladder carcinomas and dysplasia. Gut 1996;38:426-9.
9. Ajiki T, Onoyama H, Yamamoto M, et al. p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions. Hepatogastroenterology 1996;43:521-6.
10. Hanada K, Tsuchida A, Iwao T, et al. Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol 1999;94:1638-42.
11. Itoi T, Watanabe H, Ajioka Y, et al. APC, K-ras codon 12 mutations and p53 gene expression in carcinoma and adenoma of the gall-bladder suggest two genetic pathways in gall-bladder carcinogenesis. Pathol Int 1996;46:333-40.
12. Kiguchi K, Carbajal S, Chan K, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 2001;61:6971-6.
13. Kohya N, Miyazaki K, Matsukura S, et al. Deficient expression of O(6)-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. Ann Surg Oncol 2002;9:371-9.
14. Quan ZW, Wu K, Wang J, et al. Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg 2001;193:380-3.
15. Roa I, Villaseca M, Araya J, et al. p53 tumour suppressor gene protein expression in early and advanced gallbladder carcinoma. Histopathology 1997;31:226-30.
16. Suzuki T, Takano Y, Kakita A, Okudaira M. An immunohistochemical and molecular biological study of c-erbB-2 amplification and prognostic relevance in gallbladder cancer. Pathol Res Pract 1993;189:283-92.
17. Tanno S, Obara T, Fujii T, et al. Proliferative potential and K-ras mutation in epithelial hyperplasia of the gallbladder in patients with anomalous pancreaticobiliary ductal union. Cancer 1998;83:267-75.
18. Wistuba II, Albores-Saavedra J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 1999;6:237-44.
19. Shi YZ, Hui AM, Li X, et al. Overexpression of retinoblastoma protein predicts decreased survival and correlates with loss of p16INK4 protein in gallbladder carcinomas. Clin Cancer Res 2000;6:4096-100.
20. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321:209-13.
21. Baylin S. DNA methylation and epigenetic mechanisms of carcinogenesis. Dev Biol 2001;106:85-7: discussion 143-60.
22. Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-92.
23. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994;91:9700-4.
24. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998;95:6870-5.
25. Ahrendt SA, Eisenberger CF, Yip L, et al. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma. J Surg Res 1999;84:88-93.
26. Lee S, Kim WH, Jung HY, et al. Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol 2002;161:1015-22.
27. Tannapfel A, Benicke M, Katalinic A, et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000;47:721-7.
28. Tannapfel A, Sommerer F, Benicke M, et al. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol 2002;197:624-31.
29. Wong N, Li L, Tsang K, et al. Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. J Hepatol 2002;37:633-9.
30. Gerdes B, Ramaswamy A, Kersting M, et al. p16(INK4a) alterations in chronic pancreatitis-indicator for high-risk lesions for pancreatic cancer. Surgery 2001;129:490-7.
31. Taniai M, Higuchi H, Burgart LJ, Gores GJ. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002;123:1090-8.
32. Issa JP, Ahuja N, Toyota M, et al. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001;61:3573-7.
33. Azarschab P, Porschen R, Gregor M, et al. Epigenetic control of the E-cadherin gene (CDH1) by CpG methylation in colectomy samples of patients with ulcerative colitis. Genes Chromosomes Cancer 2002;35:121-6.
34. Paimela H, Karppinen A, Hockerstedt K, et al. Poor prognosis of gallbladder cancer persists regardless of improved diagnostic methods. Incidence and results of surgery during 20 years in Helsinki. Ann Chir Gynaecol 1997;86:13-7.
35. Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
36. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-8.
37. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
38. House MG, Guo M, Iacobuzio-Donahue C, Herman JG. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 2003;24:193-8.
39. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
40. Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000;60:1835-9.
41. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168-74.
42. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
43. Wistuba II, Miquel JF, Gazdar AF, Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol 1999;30:21-5.
44. Chang HJ, Jee CD, Kim WH. Mutation and altered expression of beta-catenin during gallbladder carcinogenesis. Am J Surg Pathol 2002;26:758-66.
45. Matsubara T, Sakurai Y, Sasayama Y, et al. K-ras point mutations in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. Cancer 1996;77(8 Suppl):1752-7.
46. Kim SW, Her KH, Jang JY, et al. K-ras oncogene mutation in cancer and precancerous lesions of the gallbladder. J Surg Oncol 2000;75:246-51.
47. Miquel JF, Covarrubias C, Villaroel L, et al. Genetic epidemiology of cholesterol cholelithiasis among Chilean Hispanics, Amerindians, and Maoris. Gastroenterology 1998;115:937-46.